Malignant mast cell neoplasm Completed Phase 2 Trials for Brentuximab vedotin (DB08870)

Also known as: Malignant Mast Cell Tumors / Mast Cell Leukemia (MCL) / Leukemia, Mast Cell / Mast Cell Leukemia / Malignant-mast cell tumours / Mast-Cell Sarcoma

IndicationStatusPhase
DBCOND0007107 (Malignant mast cell neoplasm)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01807598Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaTreatment